PMcardio is a mobile AI assistant for 12-lead ECG interpretation, designed for healthcare professionals to use on iOS and Android.
Product velocity
Active
Daily rank 🇺🇸
#11
Medical · grossing
Sentiment
4.3
803 reviews
Nemesis
Kardia
The App DNA
What makes this app unique?
Clinicians hire the app for rapid, automated diagnostic support on ECG images, serving as a second opinion in high-pressure emergency workflows.
For Healthcare professionals including emergency physicians, general practitioners, nurses, paramedics, and cardiologists.
What does it look like?
Key features
Deep learning model for detecting STEMI and occlusive myocardial infarction patterns.
Visual heatmaps highlighting waveform segments that triggered specific AI diagnostic outputs.
Instant calculation of 12 clinical metrics including heart rate and intervals.
How much does it cost?
The freemium model uses a low-volume free tier to drive acquisition, with a Pro subscription gate for high-frequency professional workflows.
Velocity
Active developmentnew contentUX improvementsShow more...
The app maintains an active development pace, shipping 5 releases over the last 60 days, averaging approximately 0.58 releases per week. Development is consistently focused on clinical utility, with recent updates adding diagnostic tools like SCORE2 and subendocardial ischemia detection. The release cadence is stable, with a clear focus on expanding medical functionality rather than live-service events. The publisher provides transparent release notes detailing specific feature additions and improvements.
Who built it?
Powerful Medical
2 apps tracked · Medical
PMcardio for OrganizationsUser Sentiment
What do users think recently?
Fresh user feedback skews frustrated. Users appreciate advanced ai diagnostic capabilities provide actionable insights for medical professionals during clinical practice, but report geographic access restrictions prevent users in specific regions from utilizing the diagnostic service.
How are ratings & reviews evolving?
What users say, by theme
- Advanced AI diagnostic capabilities provide actionable insights for medical professionals during clinical practice
- Geographic access restrictions prevent users in specific regions from utilizing the diagnostic service
60 of 73 recent reviews analyzed · high confidence · Frustrated overall
Read the full review analysisUnlock 1 user request, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for PMcardio for Individuals
How's the Medical market?
PMcardio holds a #6 Grossing position in the Medical category across 20+ international markets, but its #18 Grossing rank in the US signals significant friction in the largest professional market. The gap between its diagnostic utility and regional availability limits its ability to capture the full addressable market.
Read the market outlookThe rivals identified
By AliveCor, Inc.
Kardia is the dominant market leader in ECG interpretation, leveraging a massive user base and deep integration with hardware-backed diagnostic workflows.
- Integrates directly with proprietary mobile ECG hardware to provide clinical-grade diagnostic data for users.
- Offers a closed-loop ecosystem connecting patient-recorded ECGs directly to physician review platforms.
- Maintains a high-frequency release cadence, shipping 7 updates in the last six months to ensure stability.
Unlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for PMcardio for Individuals
Where is it heading?
The diagnostic AI market is consolidating around integrated clinical workflows, leaving PMcardio exposed if it cannot resolve regional access friction. The current reliance on individual subscriptions is failing to scale, so the PM must pivot to institutional licensing to secure long-term revenue stability.
- Geographic access errors in the latest update drive high churn, which compounds the negative sentiment already visible in professional reviews.
- The launch of the LVsense module demonstrates active feature investment, signaling the team is not in maintenance mode despite sentiment headwinds.
The SWOT
- Clinical-grade diagnostic capability functions as a B2B distribution barrier
- 19 independent validation studies provide the clinical evidence required for professional adoption
- Institutional enterprise licensing would allow hospitals to integrate the tool into existing clinical systems
- Expansion into resource-limited markets via tiered pricing
Next best moves
Audit regional lockout messaging because users report being blocked without warning → reduce churn.
+ 1 more prioritized moveThe counter-intuitive read
The app's regional lockout is not just a bug…
Read the full takeFeature gaps
Direct integration with proprietary mobile ECG hardware (available in Kardia but missing here)
Since the last report: PMcardio is pivoting toward enterprise-grade clinical utility to counter declining sentiment and regional access friction.
Bottom line
PMcardio wins on clinical-grade diagnostic utility, but regional access failures and inconsistent AI outputs threaten its professional retention, so the PM must prioritize enterprise licensing to bypass individual subscription friction.
Unlock 2 critical frictions, 2 market threats, 1 more prioritized move and the analyst’s take.
Access the full report for freeReport last updated